Q2 EPS Forecast for Alto Neuroscience Increased by Analyst

Alto Neuroscience, Inc. (NYSE:ANRO) – Investment analysts at Wedbush boosted their Q2 2025 earnings per share (EPS) estimates for Alto Neuroscience in a research report issued to clients and investors on Thursday, May 15th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.68) for the quarter, up from their prior estimate of ($0.70). Wedbush has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. Wedbush also issued estimates for Alto Neuroscience’s Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.63) EPS, FY2026 earnings at ($2.23) EPS and FY2029 earnings at ($2.87) EPS.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Tuesday, May 13th. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.06.

A number of other research analysts have also recently commented on ANRO. HC Wainwright started coverage on Alto Neuroscience in a research note on Monday, April 7th. They set a “buy” rating and a $10.00 price objective on the stock. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research note on Friday, March 21st. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.40.

Alto Neuroscience Trading Up 14.6%

Shares of ANRO opened at $2.91 on Monday. The stock’s 50-day moving average is $2.35 and its two-hundred day moving average is $3.41. The stock has a market cap of $78.78 million, a PE ratio of -1.24 and a beta of 1.87. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $17.55. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. SCS Capital Management LLC acquired a new position in shares of Alto Neuroscience in the first quarter worth about $144,000. AQR Capital Management LLC acquired a new position in shares of Alto Neuroscience in the first quarter worth about $52,000. AWM Investment Company Inc. lifted its stake in shares of Alto Neuroscience by 31.1% in the first quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock worth $1,948,000 after acquiring an additional 214,153 shares in the last quarter. Armistice Capital LLC lifted its stake in shares of Alto Neuroscience by 146.2% in the first quarter. Armistice Capital LLC now owns 1,600,000 shares of the company’s stock worth $3,456,000 after acquiring an additional 950,000 shares in the last quarter. Finally, Nuveen LLC acquired a new position in shares of Alto Neuroscience in the first quarter worth about $302,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.